Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357833 · ClinicalTrials.gov registry record · Early Phase 1
Novel Imaging Markers in SPMS
A Early Phase 1 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT05357833: Completed Early Phase 1 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive, sponsored by University of Utah.
NCT05357833 is a Early Phase 1 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive that has completed, run by University of Utah. The registered enrollment target is 11 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05357833, a Early Phase 1 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions. Activity of innate immunity has been hypothesized as one of the critical pathologic processes underpinning neurologic worsening in progressive MS. As such, in the short term this project proposes to investigate USPIO uptake in SPMS lesions as a promising in vivo imaging biomarker for chronic-active lesions, as distinguished from chronic-inactive lesions.
Conditions Studied
Interventions
- DRUG Ferumoxytol infusion
- DRUG Gadoteridol
- DIAGNOSTIC_TEST MRI Brain and Cervical Spine
Study Locations (1)
Utah
- University of Utah Health Imaging and Neurosciences Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2023-09-01 |
| Phase | Early Phase 1 |
What the finished NCT05357833 record still lists
NCT05357833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Ferumoxytol infusion is the first listed.
NCT05357833 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05357833 about?
NCT05357833 is a clinical study titled "Novel Imaging Markers in SPMS". This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions. Activity of innate immunity has been hypothesized as one of the critical pathologic processes underpinn...
What is the current status of trial NCT05357833?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2022-06-01. Estimated completion is 2023-09-01.
What conditions does trial NCT05357833 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Secondary Progressive Multiple Sclerosis.
What interventions are being tested in trial NCT05357833?
The interventions under investigation include: Ferumoxytol infusion (DRUG), Gadoteridol (DRUG), MRI Brain and Cervical Spine (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05357833?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357833 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05357833's enrollment target sits among peer trials
11 302nd of 315 higher than 12 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Entire-body PET Scans for Multiple Sclerosis
RECRUITING · Early Phase 1
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
Assessment of Synaptic Density in MS
RECRUITING · Early Phase 1
-
Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis
ACTIVE NOT RECRUITING · Early Phase 1
-
Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis
ACTIVE NOT RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI